| Literature DB >> 28962404 |
Hideki Kakutani1, Osamu Aozasa2, Ema Akiyama1, Teruyuki Nakao1, Souichi Ohta1.
Abstract
Coplanar polychlorinated/brominated biphenyls (Co-PXBs) belong to a class of structurally similar chemicals known as polyhalogenated aromatic hydrocarbons. We found that the milk of Japanese primiparous and multiparous mothers was similarly contaminated with Co-PXB congeners. Co-PXBs time- and dose-dependently increased ethoxyresorufin-O-deethoxylase (EROD activity) in HepG2 cells. The EROD activity of liver microsomes collected from C57BL/6 mice exposed to these congeners substituted with one or two, and with three or five bromine atoms time-dependently decreased and increased, respectively. These results indicate that introducing bromine into the chemical frame of a polychlorinated biphenyl tends to increase CYP1A activity in vitro and in vivo and that the number substituted bromine atoms alters the metabolism profiles. If Co-PXBs are more toxic than Co-PCBs, our findings suggest that the TEQ of Co-PXBs is important for human health risk.Entities:
Keywords: 7-Ethoxyresorufin-O-deethoxylase activity; AhR, aryl hydrocarbon receptor; BFRs, brominated flame retardants; Breast milk contamination; CYP, cytochrome P450; Co-PBB, coplanar polybrominated biphenyl; Co-PCB, coplanar polychlorinated biphenyl; Co-PXB, coplanar polychlorinated/brominated biphenyl; Coplanar polychlorinated/brominated biphenyls; EROD, ethoxyresorufin-O-deethoxylase; LDH, lactate dehydrogenase; MSW, municipal solid waste; PAHs, polycyclic aromatic hydrocarbons; PCDDs/DFs, polychlorinated dibenzo-p-dioxins and dibenzofurans; PXDDs/DFs, polychlorinated/brominated dibenzo-p-dioxins and dibenzofurans; REP, relative potency; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TEF, toxic equivalency factor; TEQ, toxic equivalent
Year: 2015 PMID: 28962404 PMCID: PMC5598388 DOI: 10.1016/j.toxrep.2015.05.006
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Levels of PCDDs/DFs, PXDDs/DFs, Co-PCBs and Co-PXBs contamination in breast milk at 5 days after neonatal delivery in Japan.
| Dioxin analog | Actual concentration (pg/g lipid) | TEQ concentration (pg-TEQ/g lipid) | Daily intake (pg-TEQ/kg b.w./day) | ||||
|---|---|---|---|---|---|---|---|
| Range | Median | Average | Range | Median | Average | ||
| ∑PCDDs/DFs | 42–172 | 42 | 84 | 2.4–12 | 5.1 | 6.3 | 28.4 |
| ∑PXDDs/DFs | 0–22 | 0 | 8.8 | 0–0.012 | 0.0000085 | 0.003 | 0.014 |
| ∑Co-PCBs | 12,866–54,863 | 12,866 | 30,539 | 1.1–7.7 | 3.8 | 4.1 | 18.5 |
| ∑Co-PXBs | 12–33 | 12 | 22 | 0.46–1.1 | 0.78 | 0.8 | 3.6 |
| ∑PCDDs/DFs | 26–179 | 81 | 92 | 0.42–4.6 | 1.4 | 1.9 | 8.6 |
| ∑PXDDs/DFs | 0–11 | 0 | 2.9 | 0–0.005 | 0 | 0.001 | 0.005 |
| ∑Co-PCBs | 2138–48,999 | 10,882 | 16,516 | 0.29–7.2 | 2.9 | 3.0 | 13.5 |
| ∑Co-PXBs | 9.5–54 | 22 | 27 | 0.42–1.4 | 0.73 | 0.81 | 3.6 |
Range represents minimum to maximum concentration of dioxin analogs. Data are shown as means of duplicate samples from primiparous (n = 4) and multiparous (n = 6) donors.
Levels of PCDDs/DFs, PXDDs/DFs, Co-PCBs and Co-PXBs contamination of breast milk at 30 days after neonatal delivery in Japan.
| Dioxin analog | Actual concentration (pg/g lipid) | TEQ concentration (pg-TEQ/g lipid) | Daily intake (pg-TEQ/kg b.w./day) | ||||
|---|---|---|---|---|---|---|---|
| Range | Median | Average | Range | Median | Average | ||
| ∑PCDDs/DFs | 38–161 | 144 | 114 | 1.9–11 | 3.0 | 5.4 | 24.3 |
| ∑PXDDs/DFs | 0–8.9 | 4.8 | 4.6 | 0–0.002 | 0 | 0.001 | 0.005 |
| ∑Co-PCBs | 14,261–59,860 | 29,218 | 34,446 | 1.8–7.1 | 4.3 | 4.4 | 19.8 |
| ∑Co-PXBs | 19–35 | 25 | 26 | 0.51–0.84 | 0.76 | 0.70 | 3.2 |
| ∑PCDDs/DFs | 21–205 | 57 | 85 | 0.36–4.2 | 1.8 | 1.7 | 7.7 |
| ∑PXDDs/DFs | 0–4.4 | 0.2 | 1.2 | 0–0.004 | 0.001 | 0.002 | 0.009 |
| ∑Co-PCBs | 2749–15,441 | 11,418 | 10,257 | 0.56–3.2 | 1.1 | 1.9 | 8.6 |
| ∑Co-PXBs | 13–28 | 21 | 21 | 0.45–1.2 | 0.68 | 0.75 | 3.4 |
Range represents minimum to maximum concentration of dioxin analogs. Data are shown as means of duplicate samples from primiparous (n = 4) and multiparous (n = 6) donors.
Fig. 1Contribution rates of PCDDs/DFs, PXDDs/DFs, Co-PCBs and Co-PXB congeners to total TEQ and actual concentrations of dioxin analogs in breast milk from Japanese donors. Contribution indicated as ratios (%) of (A) total TEQ concentrations of four dioxin analogs (PCDDs/DFs, PXDDs/DFs, Co-PCBs and Co-PXBs), (B) total actual concentration of five Co-PXB congeners and (C) total TEQ concentrations of five Co-PXB congeners. TEQ concentrations of Co-PXBs were calculated based on assumption of similar toxicity between corresponding Co-PXB and Co-PCB congeners. Data are shown as means (primiparous, n = 4; multiparous, n = 6).
Levels of contamination with Co-PXB congeners in breast milk at 5 days after neonatal delivery in Japan.
| Co-PXB congener | Actual concentration (pg/g lipid) | TEQ concentration (pg-TEQ/g lipid) | Daily intake (pg-TEQ/kg b.w./day) | ||||
|---|---|---|---|---|---|---|---|
| Range | Median | Average | Range | Median | Average | ||
| #105-Br | 2.3–7.9 | 4.4 | 4.8 | 0.00007–0.0002 | 0.00013 | 0.00014 | 0.0006 |
| #118-Br | 0–5.2 | 2.0 | 2.3 | 0–0.00016 | 0.000062 | 0.000071 | 0.0003 |
| #126-Br | 1.3–4.8 | 2.6 | 2.8 | 0.13–0.48 | 0.26 | 0.28 | 1.3 |
| #126-3Br | 1.1–4.1 | 1.4 | 2.0 | 0.11–0.41 | 0.14 | 0.20 | 0.89 |
| #169-Br | 5.8–18 | 8.6 | 10 | 0.17–0.54 | 0.26 | 0.31 | 1.4 |
| #105-Br | 0–7.6 | 5 | 7.2 | 0.00006–0.001 | 0.0001 | 0.0002 | 0.00097 |
| #118-Br | 2–18 | 2.9 | 3.4 | 0–0.00023 | 0.00009 | 0.0001 | 0.0005 |
| #126-Br | 0.8–5.6 | 2.2 | 2.5 | 0.08–0.56 | 0.22 | 0.25 | 1.1 |
| #126-3Br | 0.91–3.9 | 2.2 | 2.0 | 0.091–0.39 | 0.22 | 0.20 | 0.92 |
| #169-Br | 4.5–21 | 13 | 12 | 0.14–0.62 | 0.39 | 0.36 | 1.6 |
Range represents minimum to maximum concentration of Co-PXB congeners. Data are shown as means of duplicate samples from primiparous (n = 4) and multiparous (n = 6) donors.
Levels of contamination with Co-PXB congeners in breast milk at 30 days after neonatal delivery in Japan.
| Co-PXB congener | Actual concentration (pg/g lipid) | TEQ concentration (pg-TEQ/g lipid) | Daily intake (pg-TEQ/kg b.w./day) | ||||
|---|---|---|---|---|---|---|---|
| Range | Median | Average | Range | Median | Average | ||
| #105-Br | 2.1–12 | 3.1 | 5.7 | 0.00006–0.0004 | 0.000093 | 0.000172 | 0.0008 |
| #118-Br | 6.4–8.5 | 7.9 | 7.6 | 0.0002–0.0003 | 0.00024 | 0.00023 | 0.0010 |
| #126-Br | 2.1–3.7 | 2.8 | 2.9 | 0.21–0.37 | 0.28 | 0.29 | 1.3 |
| #126-3Br | 0.47–2.7 | 1.8 | 1.7 | 0.047–0.27 | 0.18 | 0.17 | 0.75 |
| #169-Br | 6.1–9.6 | 9.3 | 8.3 | 0.18–0.29 | 0.28 | 0.25 | 1.1 |
| #105-Br | 2.3–7.2 | 3.4 | 4.1 | 0.00007–0.0002 | 0.0001 | 0.0001 | 0.0006 |
| #118-Br | 1.9–5.9 | 3.4 | 3.6 | 0.00006–0.0002 | 0.0001 | 0.0001 | 0.0005 |
| #126-Br | 1.4–6.6 | 3.4 | 3.7 | 0.14–0.66 | 0.34 | 0.37 | 1.7 |
| #126-3Br | 0.41–2.4 | 1.1 | 1.3 | 0.041–0.24 | 0.11 | 0.13 | 0.56 |
| #169-Br | 3.3–13 | 8.6 | 8.4 | 0.1–0.39 | 0.26 | 0.25 | 1.1 |
Range represents minimum to maximum concentration of Co-PXB congeners. Data are shown as means of duplicate samples from primiparous (n = 4) and multiparous (n = 6) donors.
Fig. 2Induction of cytochrome P450 1A activity in HepG2 cells incubated with Co-PXBs. HepG2 cells were incubated with 10 nM Co-PXBs for various lengths of time (A) and at various concentrations for 8 h (B), and then EROD activity was measured. Relative activity is expressed as fold induction compared with vehicle. Data are shown as means ± SD (n = 5). Abbreviations: #126-Br, 4′-monobromo-3,3′,4,5-tetrachlorobiphenyl; #126-2Br, 3,4-dibromo-3′,4′,5′-trichlorobiphenyl; #126-3Br, 3′4′5′-tribromo-3,4-dichlorobiphenyl; PBB: 3,3′,4,4′,5′-pentabromobiphenyl; PCB, 3,3′,4,4′,5-pentachlorobiphenyl.
Fig. 3CYP1A activity is enhanced in mouse liver microsomes incubated with Co-PXB. Mice were orally administered with Co-PXBs at 5, 10 and 50 nmol/kg and then EROD activity was measured in liver microsomes 2 days later (A). Mice were orally administered with Co-PXBs at 10 nmol/kg and then EROD activity was measured in liver microsomes at 1, 2 and 3 days later (B). Relative activity is expressed as fold induction compared with vehicle. Data are presented as means ± SE (n = 10). *P < 0.05 and **P < 0.01 compared with same concentration or same length of incubation with PCB. Abbreviations: #126-Br, 4′-monobromo-3,3′,4,5-tetrachlorobiphenyl; #126-2Br, 3,4-dibromo-3′,4′,5′-trichlorobiphenyl; #126-3Br, 3′4′5′-tribromo-3,4-dichlorobiphenyl; PBB, 3,3′,4,4′,5′-pentabromobiphenyl; PCB, 3,3′,4,4′,5-pentachlorobiphenyl.